Recent Research Analysts’ Ratings Changes for Tvardi Therapeutics (TVRD)

A number of research firms have changed their ratings and price targets for Tvardi Therapeutics (NASDAQ: TVRD):

• 10/20/2026 – Tvardi Therapeutics is now covered by Chardan Capital. They set a “buy” rating on the stock.
• 10/12/2026 – Tvardi Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 10/4/2026 – Tvardi Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 10/2/2026 – Tvardi Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 9/26/2026 – Tvardi Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 9/12/2026 – Tvardi Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 9/8/2026 – Tvardi Therapeutics was upgraded by Lucid Cap Mkts to “strong-buy”.
• 8/30/2026 – Tvardi Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 8/22/2026 – Tvardi Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.